|
| 36441905 | Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. | Blood Adv | 2023 |
| 37524919 | Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification. | Leukemia | 2023 |
| 37698624 | Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. | Blood Cancer Discov | 2023 |
| 37078412 | Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. | Cancer | 2023 |
| 37440338 | A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS). | Leuk Lymphoma | 2023 |
| 35258401 | Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcome. | Leuk Lymphoma | 2022 |
| 36467830 | Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia. | EJHaem | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 33705966 | A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. | Leuk Res | 2021 |
| 33495312 | Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. | Clin Cancer Res | 2021 |
| 33896620 | Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]. | Leuk Res | 2021 |
| 31061068 | Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. | Clin Cancer Res | 2019 |
| 31662918 | Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma. | Case Rep Hematol | 2019 |
| 29192651 | Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. | Mod Pathol | 2018 |
| 29860938 | Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. | N Engl J Med | 2018 |
| 30030507 | Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. | Leukemia | 2018 |
| 30267380 | Leveraging Hypomethylating Agents for Better MDS Therapy. | Curr Hematol Malig Rep | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 29663325 | A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone. | Br J Haematol | 2018 |
| 29175379 | Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. | Leuk Res | 2018 |
| 29348128 | Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. | Blood | 2018 |
| 27721426 | Isocitrate dehydrogenase mutations in myeloid malignancies. | Leukemia | 2017 |
| 28157218 | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. | Blood Cancer J | 2017 |
| 29464016 | Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia. | Oncotarget | 2017 |
| 28784769 | Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. | Proc Natl Acad Sci U S A | 2017 |
| 28696354 | A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. | Int J Mol Sci | 2017 |
| 28588020 | Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia. | Blood | 2017 |
| 28575698 | Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]. | Leuk Res | 2017 |
| 26974275 | Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary. | Bone Marrow Transplant | 2016 |
| 26440706 | p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study. | Mol Oncol | 2016 |
| 26663264 | Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better? | Am J Hematol | 2016 |
| 27740629 | Acute leukemia in adult Hispanic Americans: a large-population study. | Blood Cancer J | 2016 |
| 27736729 | KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. | Leuk Res | 2016 |
| 27686689 | An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From USÂ Community Oncology Practices. | Clin Lymphoma Myeloma Leuk | 2016 |
| 27626202 | The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia. | Leuk Res | 2016 |
| 25733005 | Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. | Br J Haematol | 2015 |
| 25623136 | Targeted therapy of acute myeloid leukemia. | Expert Rev Anticancer Ther | 2015 |
| 24333114 | Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response. | Leuk Res | 2014 |
| 24818729 | The role of inflammation in leukaemia. | Adv Exp Med Biol | 2014 |
| 24888274 | Novel myelofibrosis treatment strategies: potential partners for combination therapies. | Leukemia | 2014 |
| 22772060 | MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. | Leukemia | 2013 |
| 23931614 | Perifosine--a new option in treatment of acute myeloid leukemia? | Expert Opin Investig Drugs | 2013 |
| 23688047 | Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? | Expert Opin Pharmacother | 2013 |
| 23621771 | 5-Azacytidine for the treatment of myelodysplastic syndromes. | Expert Opin Pharmacother | 2013 |
| 23647297 | New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies. | Future Oncol | 2013 |
| 23373775 | Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. | Expert Rev Hematol | 2013 |
| 22272701 | Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? | Expert Rev Hematol | 2012 |
| 23233563 | In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? | Hematology Am Soc Hematol Educ Program | 2012 |
| 22780212 | EPHA3 as a novel therapeutic target in the hematological malignancies. | Expert Rev Hematol | 2012 |
| 22548456 | Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. | Eur J Clin Invest | 2012 |